Concepedia

Publication | Closed Access

Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer

DOI

45

Citations

19

References

2006

Year

Rajiv Puri, Victor Palit, Paul M. Loadman, Michael Flannigan, Tariq Shah, Guzanfar A. Choudry, Saurajyoti Basu, John A. Double, G. Lenaz, Shanta Chawla,
The Journal of Urology

Abstract

Intravesical administration of 4 mg/40 ml apaziquone was well tolerated and had ablative activity against superficial bladder cancer marker lesions.

References

YearCitations

Page 1